Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosisPing L. Zhang, Robert Brown|Modern Pathology|2005Cited by 62
Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamideAdan Rios, Robert Brown|Oncoscience|2016Cited by 36
A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumoursNicola Steele, Johann S. de Bono, JA Plumb et al.|Journal of Clinical Oncology|2005Cited by 19
Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic optionsRobert Brown, Keri Csencsits‐Smith|Oncotarget|2016Cited by 14
Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic optionsRobert Brown, Johannes Wolff|Oncotarget|2016Cited by 10